Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2.

Two G protein-coupled neurotensin (NT) receptors, termed NTR1 and NTR2, have been identified so far. In contrast to the NTR1, which has been extensively studied, little is known about the pharmacological and biological properties of the NTR2. In the course of characterizing NT analogs that exhibited binding selectivity for the NTR2, we discovered that this receptor constitutively activated inositol phosphate (IP) production. Here, we report on the constitutive activity of the human NTR2 (hNTR2) transfected in COS cells and on compounds that exhibit agonism, inverse agonism, and neutral antagonism at this receptor. IP levels increased linearly with time, whereas they remained constant in mock-transfected cells. Furthermore, IP production was proportional to the amount of hNTR2 present at the cell membrane. SR 48692, a nonpeptide antagonist of the NTR1, stimulated IP production, whereas levocabastine, a nonpeptide histamine H1 antagonist that binds the NTR2 but not the NTR1, behaved as a weak partial inverse agonist. NT analogs modified at position 11 of the NT molecule, in particular by the introduction of bulky aromatic D amino acids, exhibited binding selectivity at the hNTR2 and also behaved as partial inverse agonists, reversing constitutive IP production up to 50%. Finally, NT barely affected constitutive IP production but antagonized the effects of both agonist and inverse agonist compounds, thus behaving as a neutral antagonist. The unique pharmacological profile of the hNTR2 is discussed in the light of its sequence similarity with the NTR1 and the known binding site topology of NT and SR 48692 in the NTR1.

[1]  A. IJzerman,et al.  Inverse agonism at G protein‐coupled receptors: (patho)physiological relevance and implications for drug discovery , 2000, British journal of pharmacology.

[2]  T. Schwartz,et al.  Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. , 2000, Molecular pharmacology.

[3]  P. Kitabgi,et al.  Identification of Residues Involved in Neurotensin Binding and Modeling of the Agonist Binding Site in Neurotensin Receptor 1* , 2000, The Journal of Biological Chemistry.

[4]  A. Beaudet,et al.  Pharmacological, molecular and functional characterization of glial neurotensin receptors , 1999, Neuroscience.

[5]  J P Vincent,et al.  Neurotensin and neurotensin receptors. , 1999, Trends in pharmacological sciences.

[6]  J. Vincent,et al.  Pivotal role of an aspartate residue in sodium sensitivity and coupling to G proteins of neurotensin receptors. , 1999, Molecular pharmacology.

[7]  J. Costentin,et al.  Identification of the Receptor Subtype Involved in the Analgesic Effect of Neurotensin , 1999, The Journal of Neuroscience.

[8]  P Ferrara,et al.  Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. , 1998, European journal of pharmacology.

[9]  R. Leurs,et al.  Agonist-independent regulation of constitutively active G-protein-coupled receptors. , 1998, Trends in biochemical sciences.

[10]  M. Kaghad,et al.  The 100-kDa Neurotensin Receptor Is gp95/Sortilin, A Non-G-Protein-coupled Receptor* , 1998, The Journal of Biological Chemistry.

[11]  P. Kitabgi,et al.  Mutagenesis and Modeling of the Neurotensin Receptor NTR1 , 1998, The Journal of Biological Chemistry.

[12]  P. Forgez,et al.  Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells. , 1998, Life sciences.

[13]  W. Rostène,et al.  Use of Nonpeptide Antagonists to Explore the Physiological Roles of Neurotensin , 1997, Annals of the New York Academy of Sciences.

[14]  A. Beaudet,et al.  Differential Binding Profile and Internalization Process of Neurotensin via Neuronal and Glial Receptors , 1997, The Journal of Neuroscience.

[15]  E. Guillemare,et al.  Effects of SR 48692 on neurotensin-induced calcium-activated chloride currents in the Xenopus oocyte expression system: agonist-like activity on the levocabastine-sensitive neurotensin receptor and absence of antagonist effect on the levocabastine insensitive neurotensin receptor , 1997, Neuroscience Letters.

[16]  Philippe Sarret,et al.  Structure, Functional Expression, and Cerebral Localization of the Levocabastine-Sensitive Neurotensin/Neuromedin N Receptor from Mouse Brain , 1996, The Journal of Neuroscience.

[17]  P Ferrara,et al.  Molecular cloning of a levocabastine‐sensitive neurotensin binding site , 1996, FEBS letters.

[18]  M. Watson,et al.  Deletion mutation in the putative third intracellular loop of the rat neurotensin receptor abolishes polyphosphoinositide hydrolysis but not cyclic AMP formation in CHO-K1 cells. , 1994, Molecular pharmacology.

[19]  P. Soubrié,et al.  The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes , 1994, British journal of pharmacology.

[20]  R. Lefkowitz,et al.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.

[21]  P. Kitabgi,et al.  Immunological and biochemical characterization of processing products from the neurotensin/neuromedin N precursor in the rat medullary thyroid carcinoma 6-23 cell line. , 1993, The Biochemical journal.

[22]  D. Craig,et al.  The Cheng-Prusoff relationship: something lost in the translation. , 1993, Trends in pharmacological sciences.

[23]  P Ferrara,et al.  Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor , 1993, FEBS letters.

[24]  P. Kitabgi,et al.  Reduced peptide bond pseudopeptide analogues of neurotensin: binding and biological activities, and in vitro metabolic stability. , 1991, European journal of pharmacology.

[25]  W. Schütz,et al.  Interactions of purified bovine brain A1-adenosine receptors with G-proteins. Reciprocal modulation of agonist and antagonist binding. , 1991, The Biochemical journal.

[26]  Masayuki Masu,et al.  Structure and functional expression of the cloned rat neurotensin receptor , 1990, Neuron.

[27]  M. Caron,et al.  Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A Herz,et al.  Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[29]  W. Rostène,et al.  Different Subcellular Localization of Neurotensin‐Receptor and Neurotensin‐Acceptor Sites in the Rat Brain Dopaminergic System , 1988, Journal of neurochemistry.

[30]  W. Rostène,et al.  Two populations of neurotensin binding sites in murine brain: discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution. , 1987, European journal of pharmacology.

[31]  P. Laduron,et al.  Different postnatal ontogeny of two [3H]neurotensin binding sites in rat brain , 1987, Brain Research.

[32]  M. Caron,et al.  The mammalian beta 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. , 1984, Biochemistry.

[33]  P. Kitabgi,et al.  Preparation of neurotensin selectively iodinated on the tyrosine 3 residue. Biological activity and binding properties on mammalian neurotensin receptors. , 1984, Biochemical and biophysical research communications.

[34]  C. Granier,et al.  Monoiodo-[Trp11]neurotensin, a highly radioactive ligand of neurotensin receptors. Preparation, biological activity, and binding properties to rat brain synaptic membranes. , 1983, The Journal of biological chemistry.

[35]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[36]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[37]  G. Milligan,et al.  Inverse agonism at adrenergic and opioid receptors: studies with wild type and constitutively active mutant receptors. , 1997, Receptors & channels.

[38]  P. Soubrié,et al.  Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Kitabgi,et al.  Reduced peptide bond pseudopeptide analogues of neurotensin. , 1992, Peptide research.